Want to see KR:002210 full AI Analyst Report?
Dongsung Pharmaceutical Co., Ltd. (002210) Stock Price & Analysis
002210 Stock Chart & Stats
- Day’s Range
- $1,137.00 - $1,242.00
- 52-Week Range
- $973.00 - $2,525.00
- Previous Close
- $1,223.00
- Volume
- N/A
- Average Volume (3M)
- 70.13K
- Market Cap
- KRW 112.91B
- Enterprise Value
- KRW 92.76B
- Total Cash (Recent Filing)
- KRW 37.47B
- Total Debt (Recent Filing)
- KRW 38.61B
- Price to Earnings (P/E)
- ―
- Beta
- -0.02
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Dec 27, 2013
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance-Sheet Leverage
The sharp reduction in leverage improves financial flexibility and reduces balance-sheet pressure compared with 2025. A stronger equity base and more manageable debt position can help Dongsung withstand operating volatility and support future recovery efforts, although profitability must still improve.
Solid Gross-Margin Profile
A relatively solid gross margin indicates that Dongsung’s products generate meaningful value before operating expenses, while renewed top-line growth provides a foundation for recovery. If revenue expands and costs are controlled, this margin base could support improved earnings over the next several quarters.
Court Dismissal Eases Immediate Governance Pressure
The dismissal removes an immediate legal challenge involving access to accounting records and may stabilize internal oversight and control dynamics. Reduced near-term litigation pressure can help management focus on operations, although the broader management-control dispute remains relevant to governance stability.
Bears Say
Persistent Operating And Net Losses
Dongsung has not yet demonstrated stable, repeatable earnings power because operating costs continue to overwhelm gross profit. Continued operating and net losses can weaken equity, restrict internally funded investment, and make the company’s longer-term recovery dependent on sustained cost improvement.
Persistent Negative Cash Generation
Ongoing operating cash burn is a fundamental weakness because reported gross margins have not translated into liquidity. Persistent negative free cash flow increases funding and liquidity risk, limits financial flexibility, and could erode the benefit of lower leverage if cash generation does not recover.
Continuing Management-Control Dispute Risk
Although the injunction was dismissed, the dispute’s connection to broader management-control tensions leaves an ongoing governance risk. Continued internal conflict could distract leadership, complicate strategic decision-making, and create further legal or activist pressure around the company’s direction.
Dongsung Pharmaceutical Co., Ltd. News
002210 FAQ
What was Dongsung Pharmaceutical Co., Ltd.’s price range in the past 12 months?
What is Dongsung Pharmaceutical Co., Ltd.’s market cap?
When is Dongsung Pharmaceutical Co., Ltd.’s upcoming earnings report date?
How were Dongsung Pharmaceutical Co., Ltd.’s earnings last quarter?
Is Dongsung Pharmaceutical Co., Ltd. overvalued?
Does Dongsung Pharmaceutical Co., Ltd. pay dividends?
What is Dongsung Pharmaceutical Co., Ltd.’s EPS estimate?
How many shares outstanding does Dongsung Pharmaceutical Co., Ltd. have?
What happened to Dongsung Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Dongsung Pharmaceutical Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Dongsung Pharmaceutical Co., Ltd.
Dong Sung Bio Pharm.Co.,Ltd. is a South Korean company with diverse operations spanning pharmaceuticals, cosmetics, hair dye manufacturing, and photodynamic therapy. Its extensive product range includes a broad selection of over-the-counter (OTC) medications designed to treat a variety of conditions. These encompass liver ailments, menopausal symptoms, skin disorders, obesity, digestive and gum health issues, and hair loss. The company's OTC offerings also feature remedies for fever, pain, inflammation, respiratory illnesses, scar reduction, and sleep disturbances, along with antiviral, anti-diarrhea, anti-nausea, blood circulation enhancing, antifungal, and antihistamine drugs. Supplementary OTC products include keratin softeners, eye nutrition supplements, and essential vitamins. Furthermore, Dong Sung Bio Pharm produces ethical (prescription-only, or ETC) drugs. These target specific medical areas such as endocrine, gastrointestinal, circulatory, neuropsychological, and oncological conditions. Its ETC portfolio also contains analgesic and anti-inflammatory agents, dermato-urinary treatments, antiviral, antibiotic, antifungal, and antihistamine medications, as well as respiratory drugs, steroids, and ophthalmic drops. Beyond its pharmaceutical lines, the company offers a range of consumer health and personal care items. These include hair coloring products, functional health foods, medical devices, various daily necessities, muscle taping supplies, disinfectants, toothpastes, shampoos for anti-hair loss and hair growth, and sanitary pads. Dong Sung Bio Pharm.Co.,Ltd. was founded in 1957 and maintains its headquarters in Seoul, South Korea.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Won-gyun Na
- Employees
- 307
- Website
- dongsung-pharm.com
- Address
- Dongsung Building, Seoul, 01340, KR
Dongsung Pharmaceutical Co., Ltd. (002210) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 3 | 12 |
| Technical Analysis | 4 | 3 | 2 |
| Moving Averages | 2 | 0 | 10 |
